BELLUS Health Inc. (BLU)
| Market Cap | 971.12M |
| Revenue (ttm) | 9,091 |
| Net Income (ttm) | -55.00M |
| Shares Out | 125.79M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,346,282 |
| Open | 7.63 |
| Previous Close | 7.61 |
| Day's Range | 7.50 - 7.79 |
| 52-Week Range | 5.89 - 12.69 |
| Beta | -0.51 |
| Analysts | Buy |
| Price Target | 15.38 (+99.22%) |
| Earnings Date | Mar 22, 2023 |
About BLU
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada. [Read more]
Financial Performance
In 2021, BELLUS Health's revenue was 16,000, an increase of 6.67% compared to the previous year's 15,000. Losses were -71.22 million, 124.3% more than in 2020.
Financial numbers in CAD Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BLU stock is "Buy." The 12-month stock price forecast is $15.38, which is an increase of 99.22% from the latest price.
News
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offerin...
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or th...
BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US
BELLUS Health Inc (NASDAQ: BLU) (TSX:BLU) has filed a preliminary prospectus supplement to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the...
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its...
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...
Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
BELLUS Health to Participate in the William Blair Biotech Focus Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
This Small-Cap Innovator is Flying High
We may be turning the page to a new chapter where small-cap stocks re-establish their supremacy.
Here's Why Bellus Health (BLU) is a Great Momentum Stock to Buy
Does Bellus Health (BLU) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMC...
Are Medical Stocks Lagging Bellus Health (BLU) This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Wall Street Analysts See an 83% Upside in Bellus (BLU): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 83.3% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive...
BELLUS Health to Participate in the Jefferies Healthcare Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Wall Street Analysts Believe Bellus (BLU) Could Rally 32%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive...